Slingshot members are tracking this corporate initiative:
Bristol-Myers Squibb (BMY) Reaches Exclusive Worldwide Agreement with PsiOxus Therapeutics to Develop an "Armed" Oncolytic Virus NG-348 to Treat Solid Tumors
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Dec 20, 2016 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2019
Don’t see a project related to the strategic initiative you care about?
Related Keywords Exclusive Worldwide Agreement, Ng-348, Armed Oncolytic Virus, Sold Tumors